In 2006, I became founding editor in chief of PLOS Neglected Tropical Diseases, a then new journal for a growing community of scientists and public h… - Peter J. Hotez
" "In 2006, I became founding editor in chief of PLOS Neglected Tropical Diseases, a then new journal for a growing community of scientists and public health officials committed to studying the (NTDs). ...I became deeply impressed with the number of papers reporting on disease findings in middle-income countries, and even in some high-income countries. This... combined with my personal experiences after moving to Texas and seeing first-hand the endemic tropical diseases, inspired me to look more deeply into the health disparities of the poor who live in the midst of wealth. ...Many of the findings in this book are based on data and information published in [the journal].
English
Collect this quote
About Peter J. Hotez
(born 5 May 1958) is an American scientist, pediatrician, and advocate in the fields of , vaccinology, and neglected tropical disease control. He serves as founding dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at , where he is also Director of the Center for Vaccine Development and Texas Children’s Hospital Endowed Chair in Tropical Pediatrics. Hotez served previously as President of the and is a founding Editor-in-Chief of . He is also the co-director of Parasites Without Borders, a global nonprofit organization with a focus on those suffering from parasitic diseases in subtropical environments.
Also Known As
Alternative Names:
Peter J Hotez
•
Peter Hotez
•
P. J. Hotez
•
P J Hotez
•
P. Hotez
•
P Hotez
•
Hotez P
•
Hotez P.
•
Hotez P. J.
•
Hotez PJ
•
Peter Jay Hotez
Related quotes. More quotes will automatically load as you scroll down, or you can use the load more buttons.
Additional quotes by Peter J. Hotez
So we have a vaccine now in clinical trials, a vaccine that we hope will advance to the clinic soon, a Hookworm vaccine in clinical trials, a new vaccine that's moving into the clinic. I like to say that these are the most important diseases that you've never heard of. These are some of the most common afflictions of the world's population, but they mostly occur among people who live in extreme poverty... [S]o there is no model to figure out who's going to pay for them. So as a consequence, neither the biotechs nor the big pharmaceutical companies make those vaccines.
When the Chinese started putting up the data on Bioarchive in January-February, we saw a very close homology between the two, and realized that we may be sitting on a very attractive Coronavirus vaccine. Now, we're working... again with NIH, and we're working with BARDA and others to get the funding, but now we'll have that lag. ...[T]hese clinical trials are not going to go that quickly because of that immune enhancement. It's going to take time. ...[U]nfortunsately, some of my colleagues in the biotech industry are making these inflated claims. ...[Y]ou've seen this... in the newspapers, "We're going to have this vaccine in weeks..." What they're really seeing is that they can move a vaccine into clinical trials, but this will not go quickly because as we start vaccinating human volunteers, especially in areas where we have community transmission, we're going to have to proceed very slowly, very cautiously. The FDA is on top of that. They have a great team in place at the . They're aware of the problem, but it's not going to go quickly. We are going to have to follow this very slowly, cautiously, to make certain that we're not seeing that immune enhancement. So now we're hearing projections, a year, 18 months, who knows...
Loading...